This Article Full Text Full Text (PDF) All Versions of this Article: 34/5/1242    most recent 01.STR.0000067706.23777.04v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Piriyawat, P. Articles by Grotta, J. C. Search for Related Content PubMed PubMed Citation Articles by Piriyawat, P. Articles by Grotta, J. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CAFFEINE ETHANOL Medline Plus Health Information Stroke Related Collections Acute Cerebral Infarction Neuroprotectors

(Stroke. 2003;34:1242.)
© 2003 American Heart Association, Inc.

Original Contributions

Pilot Dose-Escalation Study of Caffeine Plus Ethanol (Caffeinol) in Acute Ischemic Stroke

Paisith Piriyawat, MD; Lise A. Labiche, MD; W. Scott Burgin, MD; Jaroslaw A. Aronowski, PhD James C. Grotta, MD

From the Stroke Program, Department of Neurology, University of Texas—Houston Medical School, Houston.

Correspondence to James C. Grotta, MD, 6431 Fannin St, MSB 7.044, Houston, TX 77030. E-mail James.C.Grotta{at}uth.tmc.edu

Background and Purpose— In animal models, the combination of caffeine and ethanol (caffeinol) provides robust neuroprotection at blood levels that should be easily and safely achieved in humans. This study was designed to determine the safety and tolerability of ascending doses of this combination in stroke patients.

Methods— This Food and Drug Administration–approved open-label, single-arm, dose-escalation study had 3 original dose groups: group 1, caffeine 6 mg/kg plus ethanol 0.2 g/kg; groups 2 and 3, incremental increases of caffeine and ethanol by 2 mg/kg and 0.2 g/kg, respectively. Intravenous thrombolysis was encouraged if patients qualified. Drug was started within 6 hours of stroke onset, and blood levels of caffeine and ethanol were drawn at baseline and end of infusion. The target blood caffeine and ethanol ranges were 8 to 10 µg/mL and 30 to 50 mg/dL, respectively. Clinical outcome measurements included the National Institutes of Health Stroke Scale at the end of infusion, at 24 hours, and at discharge. Potential complications from caffeine and ethanol were recorded. Cases were reviewed by an independent stroke neurologist for safety.

Results— A total of 23 patients were recruited. Target blood caffeine and ethanol levels were reached in 0 of the 4 patients in the first group. The second dose group (caffeine 8 mg/kg plus ethanol 0.4 g/kg) included 8 patients. The median end-of-infusion caffeine and ethanol levels were within the desired target ranges. Two days after infusion, 1 patient in this group with preexisting cardiac disease and end-of-infusion caffeine and ethanol levels of 10.7 µg/mL and 69 mg/dL developed reversible congestive heart failure and required transfer to an intensive care unit. The original third dose group was canceled given achievement of target blood caffeine and ethanol levels in group 2. However, 3 new dose groups were created in an attempt to minimize the dose of ethanol. Although blood levels were proportional to dose, none of these new dose groups provided optimal blood levels. Congestive heart failure occurred in 1 other patient with previously asymptomatic cardiomyopathy. No other side effects were noted. Concomitant thrombolytic therapy was given in 8 patients, 1 of whom died of intracerebral hemorrhage.

Conclusions— Caffeinol alone or combined with intravenous tissue plasminogen activator can be administered safely. Caffeine 8 mg/kg plus ethanol 0.4 g/kg produces target caffeine and ethanol levels of 8 to 10 µg/mL and 30 to 50 mg/dL, respectively. A randomized, placebo-controlled trial is needed to determine the neuroprotective effect of this combination.

Key Words: caffeine • ethanol • neuroprotection • stroke, acute

This article has been cited by other articles:

				M. J. Alberts, R. A. Felberg, L. R. Guterman, S. R. Levine, and for Writing Group 4 Atherosclerotic Peripheral Vascular Disease Symposium II: Stroke Intervention: State of the Art Circulation, December 16, 2008; 118(25): 2845 - 2851. [Full Text] [PDF]

				H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF]

				H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF]

				H. C. N. Tien, L. N. Tremblay, S. B. Rizoli, J. Gelberg, T. Chughtai, P. Tikuisis, P. Shek, and F. D. Brenneman Association Between Alcohol and Mortality in Patients With Severe Traumatic Head Injury Arch Surg, December 1, 2006; 141(12): 1185 - 1191. [Abstract] [Full Text] [PDF]

				M. Fisher, A. Davalos, A. Rogalewski, A. Schneider, E. B. Ringelstein, and W.-R. Schabitz Toward a Multimodal Neuroprotective Treatment of Stroke Stroke, April 1, 2006; 37(4): 1129 - 1136. [Abstract] [Full Text] [PDF]

				K. J. Mukamal, A. Ascherio, M. A. Mittleman, K. M. Conigrave, C. A. Camargo Jr, I. Kawachi, M. J. Stampfer, W. C. Willett, and E. B. Rimm Alcohol and Risk for Ischemic Stroke in Men: The Role of Drinking Patterns and Usual Beverage Ann Intern Med, January 4, 2005; 142(1): 11 - 19. [Abstract] [Full Text] [PDF]

				X. Zhao, S.-J. Liu, J. Zhang, R. Strong, J. Aronowski, and J. C. Grotta Combining Insulin-Like Growth Factor Derivatives Plus Caffeinol Produces Robust Neuroprotection After Stroke in Rats Stroke, January 1, 2005; 36(1): 129 - 134. [Abstract] [Full Text] [PDF]

				M. A. Schwarzschild, K. Xu, E. Oztas, J. P. Petzer, K. Castagnoli, N. Castagnoli Jr., and J.-F. Chen Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease Neurology, December 9, 2003; 61(90116): S55 - 61. [Abstract] [Full Text]